Glioblastoma vaccine shows viability; k4neo tool aids low-mutation targets

Personalized Neoantigen Dendritic Cell Vaccine in Glioblastoma - Bioengineer.org

Researchers Zhang, Chi, Liu, and colleagues published phase Ib results in Nature Communications for a personalized neoantigen-pulsed autologous dendritic cell therapy in newly diagnosed glioblastoma. The approach isolates patient dendritic cells, pulses them with tumor-specific neoantigens, and reintroduces them to activate cytotoxic T-cells against the heterogeneous tumor. This represents a direct clinical validation of personalized DC vaccine strategies for an aggressive brain cancer with limited treatment options.